Neurophet KRX:380550KOSDAQ
뉴로핏 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days2
DART filings, 7 days0
Articles tracked14since Sep 11
In Q2 2026, Neurophet reported revenue of ₩782m, up 3.6% year on year, and an operating loss of ₩5.2bn. Neurophet (뉴로핏) appeared in 2 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 28 with 2 articles. It was most often mentioned alongside Vuno and Lunit.
Filing signals 4 quarters of losses Screener
Neurophet quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩782m | +3.6% | −₩5.2bn | −₩5.7bn |
| Q1 2026 | ₩481m | -9.9% | −₩5.8bn | −₩5.7bn |
| Q3 2025 | ₩763m | +228.3% | −₩4.2bn | −₩6.8bn |
| Q2 2025 | ₩755m | +72.6% | −₩3.4bn | −₩5.9bn |
| Q1 2025 | ₩534m | – | −₩4.6bn | −₩4.8bn |
| Q3 2024 | ₩232m | – | −₩4.3bn | −₩4.2bn |
| Q2 2024 | ₩438m | – | −₩3.8bn | ₩3.3bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Neurophet top stories 2 weeks, by number of outlets
- 1
Latest Neurophet news Korean headlines
-
루닛이 끌어올린 의료AI…뷰노 평가·뉴로핏 빅파마 계약 주목[바이오맥짚기]
1 more on this story · 1 outlets
- 루닛이 끌어올린 의료AI…뷰노 평가·뉴로핏 빅파마 계약 주목[바이오맥짚기]이데일리 · Oct 28 07:01
-
뉴로핏, 아시아 생명과학 어워즈 2관왕…뇌 영상 AI·임상개발 역량 인정
1 more on this story · 1 outlets
- 뉴로핏, 아시아 바이오 어워즈 2관왕…뇌 영상 AI 임상 활용성 인정바이오타임즈 · Oct 14 11:28
-
Major뉴로핏, 맞춤형 tDCS 10개 병원 공급…10월 비급여 적용
1 more on this story · 1 outlets
- 뉴로핏, 국내 의료기관 10곳에 ‘개인 맞춤형 tDCS 솔루션’ 공급... 10월 비급여 적용인공지능신문 · Sep 29 17:44